Tests a rapid finger-prick test for HIV, hepatitis B and syphilis
Tests a rapid screening test for HIV, hepatitis B and syphilis in adults.
Key facts
- Who runs it
- bioLytical Laboratories
- Where
- Cape Town, Durban, and Johannesburg, South AfricaSee the 3 sites
- Trial code
- Registry title
- A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 18 Dec 2025
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional
- Treatments tested
- TruPlex HIV/HepB/Syphilis Rapid Test
- Record updated
- 2 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are getting tested for HIV, syphilis or hepatitis B. They give finger-prick and vein blood samples to test a new rapid test.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- People known to be HIV positive can join only if they have taken anti-retroviral treatment (ART) for less than 12 months. People currently being treated for syphilis cannot join.
- Biomarker or test result
- HIV status must be unknown, or known HIV positive with less than 12 months of ART.
Main reasons for not taking part
- Has a bleeding disorder
- Is currently being treated for syphilis
- Has received any experimental HIV vaccine
- Had an HBV vaccine within the last 7 days
- Known HIV positive and on ART for 12 months or longer
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 18 years of age or older
- Subject is able to provide and willing to sign and date the Informed Consent Form
- Subject is able to complete the required testing on the allocated testing day
- Subject able to speak/read/write English or a translator is available
- Subject is getting tested for HIV, and/or Syphilis, and/or Hepatitis B for one or more of the following reasons:; At risk for any one of the target diseases; Having signs or symptoms indicative of the target diseases; Routine testing; Note: Subjects who are pregnant and re-infected are eligible to participate
- Unknown HIV or known HIV positive status with less than 12 months of Anti-Retroviral Treatment (ART)
- Subject is willing to provide the fingerstick blood sample(s) and whole blood samples collected through venous blood draw (approximately 16 ml) required for the study
- Subject willing to participate in the study site's standard of care counselling and testing program and receive the study site's standard of care test results
Who cannot take part
- Subject has received any experimental HIV vaccine
- Subject received HBV vaccine within the last 7 days
- Known HIV positive subjects and currently on ART for 12 months or longer
- Subject has a bleeding disorder
- Any condition which, in the opinion of the Investigator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of study assessment, consent form and questionnaire etc. or bias the study outcome
- Subject is currently undergoing Syphilis treatment
This trial is currently available in South Africa.
- Epicentre Health Research (Cape Town)Cape Town, South AfricaContact: Cherie CawooodTaking people
- Epicentre Health ResearchDurban, South AfricaContact: Cherie CawoodTaking people
- Epicentre Health Research (Johannesburg)Johannesburg, South AfricaContact: Cherie CawoodTaking people
About the trial
What the trial wants to find out
The objectives of this study are as follows:
Read full original descriptionShow less
To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care settings
To evaluate the usability of the TruPlex test through:
Structured usability assessments, via a questionnaire, completed by trained operators in point-of-care settings.
To assess user interpretation accuracy through a contrived result interpretation questionnaire, where intended users evaluate a set of pre-defined test results (e.g., strong/weak positives, negatives, invalids).
To monitor test system reliability, including invalid rates.
The group in the trial
- TruPlex HIV/HepB/Syphilis Rapid Test PerformanceTreatment being tested
Capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care settings will be tested on the TruPlex HIV/HepB/Syphilis Rapid Test.
Treatment: TruPlex HIV/HepB/Syphilis Rapid Test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test by Trained Personnel at Near-Patient and Point-of-Care Settings
- Plain-language title
- Tests a rapid finger-prick test for HIV, hepatitis B and syphilisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 October 2026